Exonic Pricing Page

Analysis

The pricing structure reflects an early-stage biotech AI company positioning itself as infrastructure rather than a finished product, likely offering tiered access to computational resources or API usage rather than feature-based tiers typical of SaaS. The YC affiliation and "unsupervised" positioning suggest the page probably emphasizes technical capability and research potential over consumer-friendly simplicity, appealing to research institutions and biotech firms rather than broad enterprise adoption. Without visibility into actual pricing tiers, the notable choice is likely the framing around biological discovery velocity or model access rather than traditional per-user or per-workflow metrics common in adjacent AI tools.

Notes

YC Fall 2025. Unsupervised Biological AI